Medtronic Is About to Report Its First Earnings Since Spinning Off MiniMed. Should You Buy the Stock Before Nov. 24?
The medical device giant is expected to post another quarter of stabilizing sales.
Medtronic will release its first earnings report since spinning off its diabetes unit, MiniMed, on November 24. Following the July 2023 separation, the medical device giant experienced declining earnings in 2023 and 2024 due to supply chain issues, inflation, foreign exchange headwinds, regulatory hurdles, and post-pandemic recovery in elective procedures.
However, earnings rebounded in fiscal years 2025 and 2026, driven by stabilized costs, growth in cardiovascular and neuroscience businesses, and MiniMed's spin-off. For fiscal 2027, Medtronic anticipates revenue growth of 7.25%-7.75%. Analysts project a 6% revenue increase year-over-year and a 2% decline in adjusted EPS for the third quarter of 2027.
The company's cardiovascular and neuroscience segments are expected to remain robust. Nevertheless, the spin-off, reinvestment in higher-growth platforms, early-stage manufacturing costs, and recent acquisitions are putting pressure on Medtronic's margins. With a forward earnings multiple of 17 and a forward yield of 2.9%, the stock appears attractive, but investors should assess Medtronic's growth trajectory and margin pressures before considering it a reliable blue chip dividend play.
Rewritten by urgent.news; may contain errors — check the original.